Scarica l'app Stockscreener
1.685
4.80%
-0.085
Pre-mercato:
1.73
0.045
+2.67%
Precedente Chiudi:
$1.77
Aprire:
$1.71
Volume 24 ore:
317.60K
Relative Volume:
1.73
Capitalizzazione di mercato:
$26.81M
Reddito:
-
Utile/perdita netta:
$-11.23M
Rapporto P/E:
-2.1206
EPS:
-0.7946
Flusso di cassa netto:
$-14.83M
1 W Prestazione:
+13.09%
1M Prestazione:
+25.75%
6M Prestazione:
+34.80%
1 anno Prestazione:
+63.59%
Intervallo 1D:
$1.57
$1.74
Intervallo di 1 settimana:
$1.42
$1.78
Portata 52W:
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.685 | 28.16M | 0 | -11.23M | -14.83M | -0.7946 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Iniziato | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allarity Therapeutics Advances Stenoparib Development for Cancer Treatments and Strengthens Financial Position - Quiver Quantitative
Allarity Therapeutics Q1 net loss per share narrows - TradingView
U.S. VA backs trial of Allarity cancer drug for relapsed lung patients - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allarity Therapeutics (ALLR) posts Q1 2026 loss but lifts cash with $20M notes - Stock Titan
Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant - Stock Titan
Why Allarity (ALLR) Just Dropped -1.30% — What to Watch 2026-05-14Trade Entry - newser.com
Director Jesper Hoeiland receives 25,000-share grant at Allarity (ALLR) - Stock Titan
Director Jesper Hoeiland joins Allarity Therapeutics (ALLR) with initial Form 3 filing - Stock Titan
Allarity Therapeutics Advances Stenoparib, a Dual PARP and WNT Inhibitor with DRP® Companion Diagnostic, in Phase 2 Cancer Trials - Minichart
Allarity Highlights Stenoparib Progress in New Investor Presentation - TipRanks
Allarity details stenoparib data, CEO to speak in Europe | ALLR 8-K Filing - Stock Titan
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - The Manila Times
Allarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026 - Quiver Quantitative
Allarity CEO to outline cancer drug trial work at Stockholm forum - Stock Titan
Director at Allarity Therapeutics (ALLR) receives 45,000 RSUs in grant - Stock Titan
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics Advances Stenoparib Toward Phase 3 and FDA Approval in Ovarian Cancer with Manufacturing Milestone - Minichart
Stenoparib Phase 3 manufacturing on track as Allarity (NASDAQ: ALLR) preps trials - Stock Titan
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Investing News Network
Allarity advances stenoparib manufacturing for pivotal trial By Investing.com - Investing.com South Africa
Allarity advances stenoparib manufacturing for pivotal trial - Investing.com India
Allarity readies ovarian cancer drug with no more manufacturing cash due - Stock Titan
What Allarity (ALLR) is doing to earn customer loyalty (Institutional Demand) 2026-05-05Earnings Breakout Stocks - Newser
[ARS] Allarity Therapeutics, Inc. SEC Filing - Stock Titan
Allarity Therapeutics (NASDAQ: ALLR) details 2026 votes on ELOC, pay and equity plan - Stock Titan
Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs - Stock Titan
Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units - Stock Titan
USPTO allows Allarity (NASDAQ: ALLR) stenoparib DRP patent with exclusivity to 2039 - Stock Titan
Allarity receives USPTO patent notice for stenoparib diagnostic - Investing.com UK
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Investing News Network
Allarity receives USPTO patent notice for stenoparib diagnostic By Investing.com - Investing.com Australia
Allarity Therapeutics announces that the stenoparib drp® test has received a notice of allowance from the US Patent and Trademark Office - marketscreener.com
SEC Form 424B3 filed by Allarity Therapeutics Inc. - Quantisnow
255,103 Shares Registered for Resale by 3i, LP — Allarity (NASDAQ: ALLR) - Stock Titan
[EFFECT] Allarity Therapeutics, Inc. SEC Filing - Stock Titan
Allarity Therapeutics (NASDAQ: ALLR) updates auditor consent in S-3/A - Stock Titan
ALLR (Allarity Therapeutics Inc.) reports narrower Q3 2025 loss than expected, but shares dip slightly in today’s trading.Earnings Miss - Xã Thanh Hà
Allarity Therapeutics (NASDAQ: ALLR) highlights new stenoparib and DRP® data from AACR 2026 - Stock Titan
Allarity presents cancer drug data at AACR meeting By Investing.com - Investing.com India
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):